

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/006316 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/18 (2006.01)
A61K 35/17 (2015.01) C07K 16/28 (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2021/039961

(22) International Filing Date:

30 June 2021 (30.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/046,477 30 June 2020 (30.06.2020) US

(71) Applicant: **TENEOBIO, INC.** [US/US]; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US).

(72) Inventors: **TRINKLEIN, Nathan**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US). **HARRIS, Katherine**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US). **MALIK, Harbani**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US). **SCHELLENBERGER, Ute**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US). **VAFA, Omid**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US). **FORCE ALDRED, Shelley**; 7999 Gateway Boulevard, Suite 320, Newark, California 94560 (US).

(74) Agent: **PELLETIER, Benjamin C.** et al.; Haynes and Boone, LLP, 2323 Victory Avenue, Suite 700, Dallas, Texas 75219 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA

FIG. 1

Name	CDR1	CDR2	CDR3
BCMA heavy chain-only CDR sequences	GFTFSSNA (SEQ ID NO: 1)	ISGSGDYT (SEQ ID NO: 2)	AKEVPGGPLVDFDS (SEQ ID NO: 3)
La protein, v. 1, heavy chain CDR sequences	GYTFTHYY (SEQ ID NO: 4)	VNPSNGGT (SEQ ID NO: 5)	ARSEYDYGLGFAY (SEQ ID NO: 6)
La protein, v. 2, heavy chain CDR sequences	GYAFTHYY (SEQ ID NO: 7)	VNPSNGGT (SEQ ID NO: 5)	TRSEYDYGLGFAY (SEQ ID NO: 8)
La protein light chain CDR sequences	QSLLSRTPKNY (SEQ ID NO: 9)	WAS (SEQ ID NO: 10)	KQSYNLLT (SEQ ID NO: 11)

(57) Abstract: Multi-specific, human heavy chain antibodies (e.g., UniAbsTM) binding to BCMA are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of BCMA.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*